Drug Reference
Emtricitabine / Rilpivirine / Tenofovir Disoproxil
Antivirals for treatment of HIV infections, combinations
Fact box
- Therapeutic class
- Antivirals for treatment of HIV infections, combinations
Brand names
Complera
Available as
200 MG · Oral Tablet
Multi-ingredient product
EmtricitabineRilpivirineTenofovir Disoproxil
This medicine contains more than one active ingredient. To avoid attributing one component’s information to the whole product, structured label sections aren’t shown here — see the component pediatric notes below and the full combination label on DailyMed.
Current FDA labels (DailyMed)
- EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE TABLET, FILM COATED [LAURUS LABS LIMITED]
- COMPLERA ACCESS (EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.]
- COMPLERA (EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.]
- EMTRICITABINE, RILPIVIRINE, TENOFOVIR DISOPROXIL FUMARATE TABLET, FILM COATED [MYLAN PHARMACEUTICALS INC.]
- COMPLERA (EMTRICITABINE, RILPIVIRINE HYDROCHLORIDE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [PHYSICIANS TOTAL CARE, INC.]
Authoritative sources
Reference only — not clinical advice. Verify against current FDA labeling and consult a licensed provider. About half of pediatric drug use is off-label and is not reflected in FDA labels; absence of pediatric information does not mean a medicine is unused or unsafe in children.